v3.24.2.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash $ 2,104 $ 190
Accounts receivable 54 24
Employee advance 5
Net investment in leases, short term 65 103
Prepaid expenses and vendor deposits 163 206
Total current assets 2,386 528
Property and equipment, net 137 509
Right-to-use assets, net 257 412
Other assets:    
Net investment in leases, long term 4 17
Patents, net 279 288
Other assets 44 44
Total assets 3,107 1,798
Current liabilities:    
Accounts payable and accrued expenses, including $15 and $30 to related parties as of June 30, 2024 and December 31, 2023, respectively 2,604 4,116
Customer deposits 16
Dividends payable 105 101
Lease liability, short term 267 349
Total current liabilities 2,976 4,582
Long term liabilities:    
Lease liability, long term 15 103
Total long term liabilities 15 103
Total liabilities 2,991 4,685
Commitments and contingencies (Note 12)
Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of June 30, 2024 and December 31, 2023 105 105
Deficit    
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. 105 shares of Series C outstanding as of June 30, 2024 and December 31, 2023 (see above)
Common stock, $0.001 par value, authorized 200,000,000 shares, 15,110,846 and 9,040,043 issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 15 9
Additional paid in capital 252,311 241,988
Accumulated deficit (252,332) (245,015)
Total stockholders’ deficit attributable to BioSig Technologies, Inc. (6) (3,018)
Non-controlling interest 17 26
Total equity (deficit) 11 (2,992)
Total liabilities and equity (deficit) $ 3,107 $ 1,798

Source